Validation of the use of middlebrook 7H10 agar, BACTEC MGIT 960, and BACTEC 460 12B media for testing the susceptibility of Mycobacterium tuberculosis to levofloxacin

Journal of Clinical Microbiology

Volumn 42, Issue 11, 2004, Pages 5225-5228

  Sanders, Cynthia A ^a   Nieda, Rachel R ^a   Desmond, Edward P ^a  

^a CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEC 460 12B MEDIUM; BACTEC MGIT 960 MEDIUM; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; CONCENTRATION RESPONSE; CULTURE MEDIUM; DRUG ACTIVITY; MIDDLEBROOK 7H10 AGAR MEDIUM; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TEMPERATURE DEPENDENCE; VALIDATION PROCESS;

AGAR; ANTI-BACTERIAL AGENTS; BACTERIOLOGICAL TECHNIQUES; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; TUBERCULOSIS, PULMONARY;

ACTINOBACTERIA (CLASS); BACTERIA (MICROORGANISMS); MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; UNCULTURED ACTINOMYCETE;

EID: 8644262272     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.42.11.5225-5228.2004     Document Type: Article

References (15)

1. Bergmann, J. S., and G. L. Woods. 1997. Mycobacterial growth indicator tube for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin. Diagn. Microbiol. Infect. Dis. 27:153-156.
2. Canetti, G., W. Fox, A. Khomenko, H. T. Mahler, N. K. Menon, D. A. Mitchison, N. Rist, and N. A. Smelev. 1969. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. W. H. O. 41:21-43.
3. Cegielski, P. P., D. P. Chin, M. A. Espinal, T. R. Frieden, R. Rodriguez Cruz, E. A. Talbot, D. E. Weil, R. Zaleskis, and M. C. Raviglione. 2002. The global tuberculosis situation. Progress and problems in the 20th century, prospects for the 21st century. Infect. Dis. Clin. North Am. 16:1-58.
4. Griffith, M. E., and H. L. Bodily. 1992. Stability of antimycobacterial drugs in susceptibility testing. Antimicrob. Agents Chemother. 36:2398-2402.
5. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344.
6. Kent, P. T., and G. P. Kubica. 1995. Public health mycobacteriology: a guide for the level III laboratory, p. 159-184. Publication CDC 86-8230. U.S. Department of Health, Education, and Welfare, Centers for Disease Control and Prevention, Atlanta, Ga.
7. Mor, N., J. Vanderkolk, and L. Heifets. 1994. Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages. Antimicrob. Agents Chemother. 38:1161-1164.
8. Peloquin, C. A., S. E. Berning, G. A. Huitt, and M. D. Iseman. 1998. Levofloxacin for drug-resistant Mycobacterium tuberculosis. Ann. Pharmacother. 32:268-269,
9. Perlman, D. C., W. M. El Sadr, L. B. Heifets, E. T. Nelson, J. P. Matts, K. Chirgwin, N. Salomon, E. E. Telzak, O. Klein, B. N. Kreiswirth, J. M. Musser, and R. Hafner. 1997. Susceptibility to levofloxacin of Mycobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. AIDS 11:1473-1478.
10. Pfyffer, G. E., D. A. Bonato, A. Ebrahimzadeh, W. Gross, J. Hotaling, J. Kornblum, A. Laszlo, G. Roberts, M. Salfinger, T. Wittwer, and S. Siddiqi. 1999. Multicenter validation of susceptibility testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by using the radiometric BACTEC 460 technique and the proportion method with solid media. J. Clin. Microbiol. 37:3179-3186.
11. Rodriguez, J. C., M. Ruiz, A. Climent, and G. Royo. 2001. In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 17:229-231.
12. Ruiz-Serrano, M. J., L. Alcala, L. Martinez, M. Diaz, M. Marin, M. J. Gonzalez-Abad, and E. Bouza. 2000. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob. Agents Chemother. 44:2567-2568.
13. Tortoli, E., M. Benedetti, A. Fontanelli, and M. Tullia Simonetti. 2002. Evaluation of automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to four major antituberculosis drugs: comparison with the radiometric BACTEC 460TB method and the agar plate method of proportion. J. Clin. Microbiol. 40:607-610.
14. Xu, C., B. N. Kreiswirth, S. Sreevatsan, J. M. Musser, and K. Drlica. 1996. Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis. J. Infect. Dis. 174:1127-1130.
15. Yew, W. W., C. K. Chan, C. C. Leung, H. Chau, C. M. Tom, P. C. Wong, and J. Lee. 2003. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective studv from Hong Kong. Chest 124:1476-1481.